ivylifesciences- ivylifesciences
免疫細胞專家合作多家醫院 Expanded Access Approval News :
「臺北榮民總醫院」- 2023年1月10日
「Taipei Veterans General Hospital」- January 10, 2023
長春藤生命科學與臺北榮民總醫院合作「自體免疫細胞（CIK）」治療「第一至三期實體癌，經標準治療無效」之細胞治療技術施行計畫。
Ivy Life Sciences and Taipei Veterans General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage 1 to 3 Solid Cancers, ineffective by Standard Treatment".
「臺北榮民總醫院」- 2022年12月30日
「Taipei Veterans General Hospital」- December 30, 2022
長春藤生命科學與臺北榮民總醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫。
Ivy Life Sciences and Taipei Veterans General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「馬偕紀念醫院」- 2022年10月14日
「Mackay Memorial Hospital」- October 14, 2022
長春藤生命科學與馬偕紀念醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫。
Ivy Life Sciences and Mackay Memorial Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「臺中榮民總醫院」- 2022年1月17日
「Taichung Veterans General Hospital」- January 17, 2022
長春藤生命科學與臺中榮民總醫院合作「自體免疫細胞（CIK）」治療「第一至三期實體癌，經標準治療無效」之細胞治療技術施行計畫。
Ivy Life Sciences and Taichung Veterans General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage 1 to 3 Solid Cancers, ineffective by Standard Treatment".
「國軍高雄總醫院」- 2021年10月20日
「Kaohsiung Armed Forces General Hospital」- October 20, 2021
長春藤生命科學與國軍高雄總醫院合作「自體免疫細胞（CIK）」治療「第一至三期實體癌，經標準治療無效」之細胞治療技術施行計畫細胞製備場所。
Ivy Life Sciences and Kaohsiung Armed Forces General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage 1 to 3 Solid Cancers, ineffective by Standard Treatment".
「國軍高雄總醫院」- 2021年9月29日
「Kaohsiung Armed Forces General Hospital」- September 29, 2021
長春藤生命科學與國軍高雄總醫院合作「自體免疫細胞（CIK）」治療「血液惡性腫瘤經標準治療無效」之細胞治療技術施行計畫細胞製備場所。
Ivy Life Sciences and Kaohsiung Armed Forces General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Hematological Malignancies that have failed standard treatment".
「國泰綜合醫院」- 2021年9月24日
「Cathay General Hospital」- September 24, 2021
長春藤生命科學與國泰綜合醫院合作「自體免疫細胞（CIK）」治療「第一至三期實體癌，經標準治療無效」之細胞治療技術施行計畫。
Ivy Life Sciences and Cathay General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage 1 to 3 Solid Cancers, ineffective by Standard Treatment".
「衛生福利部雙和醫院」- 2021年4月16日
「 Shuang Ho, Ministry of Health and Welfare Hospital」- April 16, 2021
長春藤生命科學與衛生福利部雙和醫院合作「自體免疫細胞（CIK）」治療「第一至三期實體癌，經標準治療無效」之細胞治療技術施行計畫。
Ivy Life Sciences and Shuang Ho, Ministry of Health and Welfare has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage 1 to 3 Solid Cancers, ineffective by Standard Treatment".
「國立成功大學醫學院附設醫院」- 2021年3月16日
「National Cheng Kung University Hospital」- March 16, 2021
長春藤生命科學與國立成功大學醫學院附設醫院合作「自體免疫細胞（CIK）」治療「第一至三期實體癌，經標準治療無效」之細胞治療技術施行計畫細胞製備場所。
Ivy Life Sciences and National Cheng Kung University Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage 1 to 3 Solid Cancers, ineffective by Standard Treatment".
「萬芳醫院」- 2020年12月21日
「Taipei Municipal Wan Fang Hospital」- December 21, 2020
長春藤生命科學與萬芳醫院合作「自體免疫細胞（CIK）」治療「第一至三期實體癌，經標準治療無效」之細胞治療技術施行計畫。
Ivy Life Sciences and Taipei Municipal Wan Fang Hospital Wanfang Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stages 1 to 3 Solid Cancer, ineffective by Standard Treatment".
「臺中榮民總醫院」- 2020年12月21日
「Taichung Veterans General Hospital」- December 21, 2020
長春藤生命科學與臺中榮民總醫院合作「自體免疫細胞（CIK）」治療「血液惡性腫瘤經標準治療無效」之細胞治療技術施行計畫。
Ivy Life Sciences and Taichung Veterans General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Hematological Malignancies that have failed standard treatment".
「臺中榮民總醫院」- 2020年12月21日
「Taichung Veterans General Hospital」- December 21, 2020
長春藤生命科學與臺中榮民總醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫。
Ivy Life Sciences and Taichung Veterans General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「宏恩綜合醫院」- 2020年8月14日
「Country Hospital」- August 14, 2020
長春藤生命科學與宏恩綜合醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫。
Ivy Life Sciences and Country Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「衛生福利部雙和醫院」- 2020年8月14日
「 Shuang Ho, Ministry of Health and Welfare Hospital」- August 14, 2020
長春藤生命科學與衛生福利部雙和醫院合作「自體免疫細胞（CIK）」治療「血液惡性腫瘤經標準治療無效」之細胞治療技術施行計畫。
Ivy Life Sciences and Shuang Ho, Ministry of Health and Welfare has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Hematological Malignancies that have failed standard treatment".
「中山醫學大學附設醫院」- 2020年7月14日
「Chung Shan University Hospital」- July 14, 2020
長春藤生命科學與中山醫學大學附設醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫。
Ivy Life Science and Chung Shan University Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「國軍高雄總醫院」- 2020年6月16日
「Kaohsiung Armed Forces General Hospital」- June 16, 2020
長春藤生命科學與國軍高雄總醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫細胞製備場所。
Ivy Life Sciences and Kaohsiung Armed Forces General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「國立成功大學醫學院附設醫院」- 2020年6月1日
「National Cheng Kung University Hospital」- June 1, 2020
長春藤生命科學與國立成功大學醫學院附設醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫細胞製備場所。
Ivy Life Sciences and National Cheng Kung University Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「臺北市立萬芳醫院」- 2020年4月28日
「Taipei Municipal Wan Fang Hospital」- April 28, 2020
長春藤生命科學與臺北市立萬芳醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫。
Ivy Life Sciences and Taipei Municipal Wan Fang Hospital Wanfang Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「國泰綜合醫院」- 2020年4月14日
「Cathay General Hospital」- April 14, 2020
長春藤生命科學與國泰綜合醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫。
Ivy Life Sciences and Cathay General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「衛生福利部雙和醫院」- 2020年4月7日
「Shuang Ho, Ministry of Health and Welfare Hospital」- April 7, 2020
長春藤生命科學與衛生福利部雙和醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫。
Ivy Life Sciences and Shuang Ho Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「三軍總醫院」- 2019年7月22日
「Tri-Service General Hospital」- July 22, 2019
長春藤生命科學與三軍總醫院合作「自體免疫細胞（CIK）」治療「實體癌第四期」之細胞治療技術施行計畫。
Ivy Life Sciences and Tri-Service General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Stage IV Solid Cancers".
「三軍總醫院」- 2019年5月3日
「Tri-Service General Hospital」- May 3, 2019
長春藤生命科學與三軍總醫院合作「自體免疫細胞（CIK）」治療「血液惡性腫瘤經標準治療無效」之細胞治療技術施行計畫。
Ivy Life Sciences and Tri-Service General Hospital has received approval from the Ministry of Health and Welfare for the implementation of Autologous Cytokine-Induced Killer Cells (CIK) to treat "Hematological Malignancies that have failed standard treatment".